Top

Published in:

01-11-2017 | Case report

Cavernous sinus thrombosis in a patient with nephrotic syndrome

Authors: David Navarro, Ana Carina Ferreira, Helena Viana, Fernanda Carvalho, Fernando Nolasco

Published in: CEN Case Reports | Issue 2/2017

Excerpt

Nephrotic syndrome (NS) is a glomerular disease characterized by altered permeability of the glomerular capillary wall to macromolecules. This results in heavy proteinuria, hypoalbuminemia, hypercholesterolemia, lipiduria, and edema. …

Kerlin Bryce A, Ayoob Rose, Smoyer William E. Epidemiology and pathophysiology of nephrotic syndrome—associated thromboembolic disease. Clin J Am SocNephro. 2012;7(3):513–20.CrossRef

Radhakrishnan J. Renal vein thrombosis and hypercoagulable state in nephrotic syndrome. In: Post TW, editors. UpToDate. Waltham; 2017. https://www.uptodate.com/contents/renal-vein-thrombosis-and-hypercoagulable-state-in-nephrotic-syndrome. Accessed Dec 2016.

Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012;7:513–20.CrossRef

Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med. 1998;338:1202–11.CrossRef

Bauer KA. Overview of the causes of venous thrombosis. In: Post TW, editor. UpToDate. Waltham; 2017. https://www.uptodate.com/contents/overview-of-the-causes-of-venous-thrombosis. Accessed Dec 2016.

Ghedura Besbes L. Cerebral sinovenous thrombosis in a child with idiopathic nephrotic syndrome. Case Rep Nephrol. 2011;2011:724950.

Rasheed Khalid N, Fakeeh Al, Soud A Al. Cerebral venous thrombosis in the nephrotic syndrome. Saudi J Kidney Dis Transpl. 2000;11(1):59–63.PubMed

Bhoobun S, Jalloh AA, Jacobsen KH. Cerebral venous thrombosis in a child with nephrotic syndrome: case report. Pan Afr Med J. 2012;13:57.CrossRef

Ferro JM, Canhão P. Etiology, clinical features, and diagnosis of cerebral venous thrombosis. In: Post TW, editor. UpToDate. Waltham; 2017. https://www.uptodate.com/contents/etiology-clinical-features-and-diagnosis-of-cerebral-venous-thrombosis. Accessed Dec 2016.

10.

Saposnik G, Barinagarrementeria F, Brown RD, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:1158–92.CrossRef

11.

Torres RA, Torres RB, Rocha de Castilho AS, Honorato R. Venous sinus thrombosis in a child with nephrotic syndrome: a case report and literature review. Rev Bras Ter Intensiva. 2014;26(4):430–4.CrossRef

12.

Thanu S, Unni VN, Anil M, Rajesh R, George K. Cerebral venous thrombosis in nephrotic syndrome. Amrita J Med. 2014;10(2):1–44.

13.

Stan J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352:1791–8.CrossRef

14.

Akatsu H, Vaysburd M, Fervenza F, Peterson J, Jacobs M. Cerebral venous thrombosis in nephrotic syndrome. Clin Nephrol. 1997;48:317–20.PubMed

15.

Friemel SP, Mackey DW, Fenves AZ, Hise JH, Cheung EH, Stone MJ. Nephrotic syndrome presenting as dural sinus thrombosis. Am J Med. 2002;113:258–60.CrossRef

16.

Hughes G. Hughes syndrome (the antiphospholipid syndrome). Ten clinical lessons. Autoimmun Rev. 2008;7(3):262–6.CrossRef

17.

Pérez-Vázquez M, Cabiedes J, Cabral A, Alarcón-Segovia D. Decrease in serum antiphospholipid antibody levels upon development of nephrotic syndrome in patients with systemic lupus erythematosus: relationship to urinary loss of IgG and other factors. Am J Med. 1992;92(4):357–62.CrossRef

18.

Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20:206.CrossRef

19.

Giannakopoulos B, Krilis SA. How I treat the antiphospholipid syndrome. Blood. 2009;114:2020–30.CrossRef

Title: Cavernous sinus thrombosis in a patient with nephrotic syndrome
Authors: David Navarro
Ana Carina Ferreira
Helena Viana
Fernanda Carvalho
Fernando Nolasco
Publication date: 01-11-2017
Publisher: Springer Singapore
Published in: CEN Case Reports / Issue 2/2017
Electronic ISSN: 2192-4449
DOI: https://doi.org/10.1007/s13730-017-0260-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2017

A case of mild phenotype Alport syndrome caused by COL4A3 mutations

Diffuse large B-cell lymphoma presenting as bilateral renal infiltration leading to acute kidney injury

Primary Ewing sarcoma of the kidney: a case report and treatment review

List of referees

Peritoneal dialysis-associated catheter infection caused by Mycobacterium abscessus in an elderly patient who was successfully treated with catheter removal

Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials